Bristol-Myers Squibb (BMY) Misses Q4 EPS by 4c; Guides Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results
January 26, 2017 6:59 AM ESTIncreases Fourth Quarter Revenues 22% to $5.2 Billion, 17% for Full Year to $19.4 Billion Posts Fourth Quarter GAAP EPS of $0.53 and Non-GAAP EPS of $0.63 Announces Settlement and License Agreement to Resolve PD-1 Patent Litigation Against Merck Achieves Important Regulatory Milestones for Opdivo Approved in the U.S. for Metastatic Squamous Cell Carcinoma of the Head and Neck Approved in Europe for Classical Hodgkin Lymphoma Completes Strategic Transactions in Oncology and Fibrosis... More
